Arresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors

Cardiovascular Research

Volumn 39, Issue 2, 1998, Pages 301-311

  Brooks, Gavin ^a,b   Poolman, Robert A ^a   Li, Jian Mei ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Prolifix Ltd   (United Kingdom)

Author keywords

Cell cycle; CIP KIP; Cyclin; Cyclin dependent Kinase inhibitor; Heart; Myocyte

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; RETINOBLASTOMA PROTEIN;

CELL CYCLE; CELL MATURATION; CELL PROLIFERATION; ENZYME ACTIVITY; HEART DEVELOPMENT; HEART HYPERTROPHY; HEART MUSCLE CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0032145311     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00125-4     Document Type: Review

References (112)

1. [1] Claycomb WC. Control of cardiac muscle cell division. Trends Cardiovasc Med 1992;2:231-236.
2. [2] Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 1996;28:1737-1746.
3. [3] Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol 1996;271:H2183-H2189.
4. [4] Capasso JM, Bruno S, Cheng W, et al. Ventricular loading is coupled with DNA synthesis in adult cardiac myocytes after acute and chronic myocardial infarction in rats. Circ Res 1992;71:1379-1389.
5. [5] Marino TA, Haldar S, Williamson EC, et al. Proliferating cell nuclear antigen in developing and adult rat cardiac muscle cells. Circ Res 1991;69:1353-1360.
6. [6] Rumyantsev PP. Proliferative activity of cardiomyocyte and polyploidization of their nuclei during myocardial hypertrophy of non-primates In: Growth and hyperplasia of cardiac muscle cells, Carlson BM, editor, pp. 231-238. Soviet Medical Reviews Supplement Cardiology. Vol 3. Harwood Academic Press, 1991.
7. [7] Anversa P, Palackal T, Sonnenblick EH, Olivetti G, Capasso JM. Hypertensive cardiomyopathy: myocyte nuclei hyperplasia in the mammalian rat heart. J Clin Invest 1990;85:994-997.
8. [8] Olivetti G, Ricci R, Anversa P. Hyperplasia of myocyte nuclei in long-term cardiac hypertrophy in rats. J Clin Invest 1987;80:1818-1821.
9. [9] Kannel WB, Doyle JT, McNamara PM. Precursors of sudden coronary death. Factors related to incidence of sudden death. Circulation 1975;51:606-613.
10. [10] Halt PY. Experimental models. In: Swynghedauw B, editor. Research in cardiac hypertrophy and failure. London: Inserm/John Libby Eurotext, 1990:Ch. 2, pp. 13-22.
11. 2+ exchanger in end-stage human heart failure. Circ Res 1994;75:443-453.
12. [12] Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: Molecular studies of an adaptive physiologic response. FASEB J 1991;5:3037-3046.
13. [13] Charlemagne D, Orlowski J, Oliviero P, et al. Alteration of Na, K-ATPase subunit mRNA and protein levels in hypertrophied rat heart. J Biol Chem 1994;269:1541-1547.
14. 2+ exchanger in response to cardiac pressure overload. Am J Physiol 1993;265:H1024-H1029.
15. [15] Gillespie-Brown J, Fuller SJ, Bogoyevitch MA, Cowley S, Sugden PH. The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. J Biol Chem 1995;270:28092-28096.
16. [16] Orlowski J, Lingrel JB. Thyroid and glucocorticoid hormones regulate the expression of multiple Na,K-ATPase genes in cultured neonatal rat cardiac myocytes. J Biol Chem 1988;263:10436-10442.
17. 2+ exchange activity and ex-changer immunoreactivity in developing rabbit hearts. Am J Physiol 1992;263:H1506-H1513.
18. 2+ exchanger peak near birth in de-veloping rabbit and rat hearts. Circ Res 1994;74:354-359.
19. [19] Li J-M, Brooks G. Down-regulation of the cyclin dependent kinase inhibitors, p21 and p27, in pressure overload hypertrophy. Am J Physiol 1997;273:H1358-H1367.
20. [20] McGill CJ, Brooks G. Cell cycle control mechanisms and their role in cardiac growth. Cardiovasc Res 1995;30:557-569.
21. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-2952.
22. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-261.
23. [23] Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
24. [24] Kamb A, Grus NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
25. [25] Hirai H, Roussel MF, Kato J-Y, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-2681.
26. [26] Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
27. [27] Jiang H, Lin J, Fisher PB. A molecular definition of terminal differentiation in human melanoma cells. Mol Cell Differentiation 1994;2:221-239.
28. [28] Polyak K, Kato J-Y, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
29. [29] Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
30. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-649.
31. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-662.
32. [32] Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366:707-710.
33. [33] Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
34. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
35. INK4. Mol Cell Biol 1995;15:2682-2688.
36. [36] Noda A, Ning Y, Venable SF, et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-98.
37. [37] Lin J, Reichner C, Wu X, Levine AJ. Analysis of wild-type and mutant p21WAF1 gene activities. Mol Cell Biol 1996;16:1786-1793.
38. [38] Li Y, Jenkins CW, Nichols MA, et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994;9:2261-2268.
39. Sdi1 antisense RNA. Proc Natl Acad Sci USA 1995;92:4352-4356.
40. Sdi1/CIP1/WAF1. EMBO J 1995;14:555-563.
41. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995;92:6289-6293.
42. [42] Harper JW, Elledge SJ, Ketomarsi K, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995;6:387-400.
43. [43] Peters G. Stifled by inhibitions. Nature 1994;371:204-205.
44. [44] Gyuris J, Golemis E, Chertkov H, Brent R, et al. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 1993;75:791-803.
45. [45] Huppi K, Siwarski J, Dosik J, et al. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene 1994;9:3017-3020.
46. [46] El-Deiry WS, Tokino T, Velcelescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993;75:817-825.
47. [47] Jiang H, Fisher PB. Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol Cell Differentiation 1993;1:285-299.
48. CIP1. Nature 1995;375:159-164.
49. [49] Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995;374:386-388.
50. CIP1. Mol Cell Biol 1996;16:4673-4682.
51. [51] Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993;7:1572-1583.
52. [52] Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-537.
53. [53] Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994;8:1750-1758.
54. [54] Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-1021.
55. [55] Gorospe M, Liu Y, Xu Q, Chrest FJ, Holbrook NJ. Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol 1996;16:762-770.
56. [56] Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-557.
57. [57] Guo K, Wang J, Andres V, Smith RC, Walsh K. Myo D-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 1995;15:3823-3829.
58. [58] Wang J, Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 1996;273:359-361.
59. [59] Jiang H, Lin J, Su Z-Z, et al. Induction of differentiation in human promyelocytic HL-60 leukaemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1995;9:3397-3406.
60. [60] Poluha W, Poluha DK, Chang B, et al. The cyclin-dependent kinase inhibitor p21WAF1 is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 1996;16:1335-1341.
61. [61] Missero C, Calautti E, Eckner R, et al. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 1995;92:5451-5455.
62. Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-1027.
63. [63] Yang Z-Y, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1995;1:1052-1056.
64. [64] Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-716.
65. Waf is contained in its N-terminal half ("half-WAF"). Oncogene 1995;11:393-395.
66. 1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
67. [67] Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-1023.
68. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994;8:2540-2551.
69. [69] Datto MB, Li Y, Panus JF, et al. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995;92:5545-5549.
70. [70] Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-3395.
71. [71] Russo T, Zambrano N, Esposito F, et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 1995;270:29386-29391.
72. [72] Gartenhaus RB, Wang P, Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukaemia virus type 1-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc Natl Acad Sci USA 1996;93:265-268.
73. [73] Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 1994;11:59-64.
74. [74] Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-684.
75. [75] Shiohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781-3784.
76. [76] Poolman RA, Brooks G. Expression of CIP/KIP family of cyclin-dependent kinase inhibitors during cardiac development. Circulation 1996;94:A0909.
77. [77] Su J-Y, Rempel RE, Erikson E, Maller JL. Cloning and characterization of the Xenopus cyclin-dependent kinase inhibitor p27xic1. Proc Natl Acad Sci USA 1995;92:10187-10191.
78. [78] Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996;382:325-331.
79. [79] Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994;91:5291-5295.
80. [80] Hengst L, Reed SI. Translational control of p27KIP1 accumulation during the cell cycle. Science 1996;271:1861-1864.
81. KIP1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-496.
82. [82] Winston J, Dong F, Pledger WJ. Differential modulation of G1 cyclins and the Cdk inhibitor p27kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. J Biol Chem 1996;271:11253-11260.
83. [83] Agrawal D, Hauser P, McPherson F, et al. Repression of p27Kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell Biol 1996;16:4327-4336.
84. [84] Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272:877-880.
85. [85] Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
86. [86] Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumours. Cell 1996;85:707-720.
87. [87] Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27-deficient mice. Cell 1996;85:733-744.
88. [88] Kiyokawa H, Kineman RD, Manova-Tadorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27. Cell 1996;85:721-732.
89. KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-158.
90. [90] Burton PBJ, Yacoub MH, Barton PJR. Cell cycle regulatory molecule expression during heart development. J Mol Cell Cardiol 1997;29:A41.
91. [91] Flink IL, Oana S, Bahl JJ, Morkin E. Terminal differentiation in cardiomyocytes results from hypophosphorylation of retinoblastoma protein by induction of cyclin-dependent kinase inhibitory activities. Circulation 1996;94:A2745.
92. [92] Poolman RA, Brooks G. Braking the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors. BSCR Bull 1997;10(1):4-10.
93. [93] Brooks G, Poolman RA, McGill CJ, Lim J-M. Expression and activities of cyclins and cyclin-dependent kinases in developing rat ventricular myocytes. J Mol Cell Cardiol 1997;29:2261-2271.
94. [94] McGill CJ, Poolman RA, Brooks G. Expression of cell cycle molecules during development of rat cardiac myocytes. J Mol Cell Cardiol 1996;28:A76.
95. [95] Waga S, Hannon GL, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
96. [96] Poolman RA, Li J-M, Brooks G. Altered expression of cell cycle regulatory proteins in p27 knockout mice. Circulation 1997;96(8):I-6.
97. [97] Dimri GP, Nakanishi M, Desprez P-Y, Smith JR, Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 1996;16:2987-2997.
98. [98] Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of the cyclin A gene promotor is mediated by a variant E2F site. Proc Natl Acad Sci USA 1995;92:11264-11268.
99. [99] Li J-M, Poolman RA, Brooks G. Up-regulation of G1 cyclins and CDKs during cardiomyocyte hypertrophy. J Mol Cell Cardiol 1998, in press (Abstr.)
100. [100] Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;275:506-510.
101. [101] Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-depen-dent cell-cycle inhibition by the tumour suppressor p 16. Nature 1995;375:503-506.
102. [102] Tarn SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res 1994;54:5816-5820.
103. [103] Lee M-H, Nikolic M, Baptista CA, et al. The brain-specific activator p35 allows Cdk5 to escape inhibition by p27Kip1 in neurons. Proc Natl Acad Sci USA 1996;93:3259-3263.
104. INK4 deletions with monosomy 5 in kidney epithelial cell lines but not primary renal tumors. Cancer Res 1995;55:1607-1612.
105. INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-11049.
106. [106] He J, Allen JR, Collins VP, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-5807.
107. [107] Li J-M, Nichols MA, Chandrasekharan S, Xiong Y, Wang X-F. Transforming growth factor β activates the promotor of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem 1995;270:26750-26753.
108. [108] Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRB. Cancer Res 1994;54:6078-6082.
109. [109] Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 1995;270:18195-18197.
110. [110] Steinman RA, Hoffman B, Iro A, et al. Induction of p21 (WAF-1/ CIP1) during differentiation. Oncogene 1994;9:3389-3396.
111. [111] Sheikh MS, Li X-S, Chen J-C, et al. Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal pathways. Oncogene 1994;9:3407-3415.
112. [112] Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 1995;267:1022-1024.